Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

BACKGROUND: The hypomethylating agent decitabine is the standard therapy for intermediate or high risk myelodysplastic syndrome (MDS). METHODS: In this trial, 191 adult patients with intermediate/high risk MDS (IPSS score ≥ 0.5) randomly received decitabine using a standard regimen (20 mg/m(2)/day f...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui, Jiang, Hao, Tong, Hongyan, Xia, Ruixiang, Yang, Linhua, Zhao, Hongguo, Ouyang, Jian, Bai, Hai, Sun, Hui, Hou, Li, Jiang, Ming, Zeng, Yun, Liu, Zhuogang, Liang, Aibin, Xie, Yinghua, Yu, Kang, Zhai, Zhimin, Liu, Li, Jia, Jinsong, Fu, Rong, Shao, Zonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358210/
https://www.ncbi.nlm.nih.gov/pubmed/37350499
http://dx.doi.org/10.1002/cam4.5922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358210/
https://www.ncbi.nlm.nih.gov/pubmed/37350499
http://dx.doi.org/10.1002/cam4.5922

Ejemplares similares